医药行业文章摘要标题梳理：2023年ESMO重点创新药进展跟踪

丁丹（分析师） 邮箱：dingdan@gtjas.com电话：0755-23976735 证书编号：S0880514030001 甘坛焕（分析师） 电话：021-38675855 证书编号：S0880523080007 唐玉青（研究助理） 电话：021-38031031 证书编号：S0880123070133 ESMO 《2023年ESMO重点创新药进展跟踪》 (ESMOcongress)2023ESMO2023 1020-24 02 Oral,O ESMO MiniOral,MOPoster,P 01 Late-breakingabstracts,LBA 2023ESMO 1 PD-1 IO2TIGHTKRASG12C 3 ADC 2 2023ESMO LBA 2023ESMO 《2023年ESMO重点创新药进展跟踪》 HRS-4642 KRASG12D Afirst-in-humanphase1studyofanovelKRASG12DinhibitorHRS-4642inpatientswithadvancedsolidtumorsharboringKRASG12Dmutation KRASG12DHRS-4642KRASG12D1 LBA33 PD-1 Neoadjuvantshort-courseradiotherapyfollowedbycamrelizumabpluschemotherapyversuslong-coursechemoradiotherapyfollowedbychemotherapyinlocallyadvancedrectalcancer:arandomizedphaseIIItrial(UNION) IIIUNION LBA25 + PD-1/ + Camrelizumabplusfamitinibversuscamrelizumabaloneandinvestigator'schoiceofchemotherapyinwomenwithrecurrentormetastaticcervicalcancer LBA44 + PD-1/VEGFR-2 + Perioperativecamrelizumab(C)combinedwithrivoceranib(R)andchemotherapy(chemo)versuschemoforlocallyadvancedresectablegastricorgastroesophagealjunction(G/GEJ)adenocarcinoma:thefirstinterimanalysisofarandomized,phase3trial(DRAGONIV) G/GEJ 3DRAGONIV 1512MO NeoadjuvantCamrelizumabandApatinibinPatientswithResectableNon-Small-CellLungCancer:One-YearUpdateFromaPhase2Trial 21 1296P 3 2023ESMO SHR-A1811 HER2 ADC TheHER2-targetingADCSHR-A1811inHER2-expressing/mutatedadvancednon-breastsolidtumors(STs):resultsfromtheglobalphase1study 656MO Phase1trialofSHR-A1811inHER2-expressingadvancedgastriccancer(GC)orgastroesophagealjunctionadenocarcinoma(GEJ)andcolorectalcancer(CRC) 684P SHR-A2009 HER3 ADC Phase1studyofSHR-A2009,aHER3-targetedADC,inadvancedsolidtumors 658MO SHR-1701 PD-L1/TGF-βRII Aphase1b/2studyofSHR-1701(abifunctionalanti-PD-L1/TGF-βRIIagent)incombinationwithbevacizumab(BEV)inpatientswithadvancedsolidtumors 1026MO SHR-1701incombinationwithBP102andXELOXasfirst-line(1L)treatmentforpatients(pts)withunresectablemetastaticcolorectalcancer(mCRC):datafromaphase2/3study 611P 2023ESMO 《2023年ESMO重点创新药进展跟踪》 4 2023ESMO 《2023年ESMO重点创新药进展跟踪》 PD-1 Tislelizumab(TIS)PlusChemotherapy(Chemo)vsPlacebo(PBO)PlusChemoasFirst-Line(1L)TreatmentofAdvancedGastricorGastroesophagealJunctionAdenocarcinoma(GC/GEJC):Final AnalysisResultsoftheRATIONALE-305Study LBA80 PathologicalResponsetoNeoadjuvantTislelizumab(TIS)PlusPlatinum-Doublet(PtDb)Chemotherapy(CT)inResectableStageII-IIIANSCLCPatients(pts)inthePhase3(Ph3) RATIONALE-315Trial LBA58 + + PD-1/TIGHT/VEGFR AdvanTIG-206:PhaseIIrandomizedopen-labelstudyofociperlimab(OCI)+tislelizumab(TIS)+BAT1706(bevacizumabbiosimilar)versusTIS+BAT1706inpatients(pts)withadvanced hepatocellularcarcinoma(HCC) 945MO + PD-1/TIGHT AdvanTIG-203:PhaseIIrandomized,multicenterstudyofociperlimab(OCI)+tislelizumab(TIS)inpatients(pts)withunresectable,locallyadvanced,recurrent/metastaticesophagealsquamouscell carcinoma(ESCC)andprogrammedcelldeath-ligand1(PD-L1)positivity 1020MO PD-1/TIGHT AdvanTIG-202:PhaseIIrandomized,multicenter,open-labelstudyoftislelizumab(TIS)withorwithoutociperlimab(OCI)inpatients(pts)withpreviouslytreatedrecurrent/metastatic(R/M)cervicalcancer(CC) 744MO 2023ESMO5 2023ESMO DP303c HER2ADC ADC Amulticenter,open-label,doseescalationandexpansionstudyofDP303cinpatientswithHER2-postivepre-treatedadvancedsolidtumors. 385MO SYHA1813 VEGFR/CSF-1R AphaseIdose-expansioncohortofSYHA1813,avascularendothelialgrowthfactorreceptor(VEGFR)1-3/colony-stimulatingfactor1receptor(CSF1R)inhibitor,inpatients(pts)withrecurrentmeningioma. 506MO HS-20089 B7H4ADC ADC First-in-human/phaseItrialofHS-20089,aB7-H4ADC,inpatientswithadvancedsolidtumors. 381MO EGFR EGFR Aumolertinibplusapatinibversusaumolertinibasfirst-linetreatmentinpatientswithEGFRmutationpositivelocallyadvancedormetastatinon-smallcelllungcancer(NSCLC):arandomizedmulticenterstudy LBA69 2023ESMO 《2023年ESMO重点创新药进展跟踪》 6 2023ESMO Anlotinibpluschemotherapyasfirst-linetherapyforgastrointestinaltumorpatientswithunresectablelivermetastasis:preliminaryresultsfromamulti-cohort,multi-centerphaseIItrial(ALTER-G-001) 1628P Phase2studyofanlotinibcombinedwithtaxanesandlobaplatinintheneoadjuvanttreatmentoftriple-negativebreastcancer:efficacy,safetyandbiomarkeranalysisfromtheneoALTALtrial 246P + PD-L1/ + UpdateresultsofanlotinibcombinedwithTQB2450(PD-L1blockade)asfirst-linetreatmentforadvancedesophagealsquamouscellcarcinoma(ESCC):asingle-arm,multicenter,open-labelphaseⅡclinicaltrial 1531P + PD-1/ + Penpulimab+anlotinibpluschemo-lesstherapyinfirst-linetreatmentforpersistent,recurrent,ormetastaticcervicalcancer:asingle-arm,phaseⅡstudy(ALTN-AK105-II-06) 763P 2023ESMO 《2023年ESMO重点创新药进展跟踪》 7 2023ESMO 《2023年ESMO重点创新药进展跟踪》 + PD-1/ + Penpulimab+anlotinibpluschemo-lesstherapyinfirst-linetreatmentforpersistent,recurrent,ormetastaticcervicalcancer:asingle-arm,phaseⅡstudy(ALTN-AK105-II-06) 763P () PD-1/VEGFR HARMONi:Randomized,double-blind,multi-center,phaseIIIclinicalstudyofivonescimaborplacebocombinedwithpemetrexedandcarboplatininpatientswit